Dermatophytosis affects over 35–40% of the Asian population, making it a significant public health challenge, especially in lower-socioeconomic regions because of crowded living conditions and poor hygiene. Therefore, researchers are constantly on the lookout for novel antifungal agents to manage chronic or recurring dermatophytosis.
Luliconazole is a novel topical antifungal agent with a distinct chemical structure and has outperformed other antifungal drugs in several in vitro studies. This graphical abstract provides detailed insights into the efficacy of topical luliconazole treatment in tinea pedis patients.